Evolent Health (NYSE:EVH) Price Target Lowered to $15.00 at JPMorgan Chase & Co.

Evolent Health (NYSE:EVH) had its price target reduced by research analysts at JPMorgan Chase & Co. from $45.00 to $15.00 in a report released on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the technology company’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 29.31% from the company’s current price.

Other equities analysts have also recently issued reports about the company. Oppenheimer decreased their target price on Evolent Health from $34.00 to $28.00 and set an “outperform” rating on the stock in a report on Monday. Stephens cut shares of Evolent Health from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $38.00 to $16.00 in a research note on Friday, November 8th. KeyCorp began coverage on shares of Evolent Health in a research report on Friday, October 11th. They set an “overweight” rating and a $35.00 price objective for the company. Royal Bank of Canada restated an “outperform” rating and set a $20.00 price target on shares of Evolent Health in a report on Tuesday, November 12th. Finally, Truist Financial restated a “buy” rating and issued a $33.00 target price on shares of Evolent Health in a report on Tuesday, August 27th. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $25.90.

Evolent Health Stock Up 0.1 %

Shares of EVH stock traded up $0.01 during trading hours on Friday, hitting $11.60. 253,167 shares of the company’s stock traded hands, compared to its average volume of 1,781,558. Evolent Health has a 12-month low of $11.17 and a 12-month high of $35.00. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of -12.74 and a beta of 1.58. The stock’s fifty day simple moving average is $23.63 and its two-hundred day simple moving average is $23.91. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58.

Institutional Trading of Evolent Health

Hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. grew its position in Evolent Health by 3.2% in the 2nd quarter. Principal Financial Group Inc. now owns 15,594 shares of the technology company’s stock valued at $298,000 after buying an additional 480 shares during the last quarter. Ascent Group LLC grew its holdings in shares of Evolent Health by 2.8% during the first quarter. Ascent Group LLC now owns 20,330 shares of the technology company’s stock worth $667,000 after buying an additional 550 shares in the last quarter. SeaCrest Wealth Management LLC boosted its holdings in shares of Evolent Health by 6.3% during the second quarter. SeaCrest Wealth Management LLC now owns 10,200 shares of the technology company’s stock worth $195,000 after purchasing an additional 600 shares during the last quarter. American International Group Inc. grew its holdings in Evolent Health by 1.2% in the 1st quarter. American International Group Inc. now owns 55,402 shares of the technology company’s stock valued at $1,817,000 after buying an additional 640 shares during the period. Finally, Arizona State Retirement System raised its stake in Evolent Health by 2.3% during the second quarter. Arizona State Retirement System now owns 29,083 shares of the technology company’s stock worth $556,000 after purchasing an additional 649 shares during the period.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.